Into the Clinic With Nivolumab and Pembrolizumab

Catherine A Shu; Naiyer A Rizvi

doi:10.1634/theoncologist.2016-0099

Into the Clinic With Nivolumab and Pembrolizumab

Oncologist. 2016 May;21(5):527-8. doi: 10.1634/theoncologist.2016-0099. Epub 2016 Mar 29.

Authors

Catherine A Shu¹, Naiyer A Rizvi²

Affiliations

¹ Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA.
² Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA [email protected].

Abstract

In 2015, the US Food and Drug Administration approved the use of nivolumab for treatment of squamous and nonsquamous non-small cell lung cancer (NSCLC) and pembrolizumab for use in patients with NSCLC tumors that express PD-L1. This commentary discusses issues with these two drugs relative to best practices and target populations.

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
B7-H1 Antigen / biosynthesis
Carcinoma, Non-Small-Cell Lung / drug therapy*
Gene Expression Regulation, Neoplastic / drug effects
Humans
Nivolumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
B7-H1 Antigen
CD274 protein, human
Nivolumab
pembrolizumab